CSPC Innovation Pharmaceutical's (SHE:300765) first-in-class PD-1/IL-15 bispecific fusion protein, SYS6090 (JMT108), received a fast track designation from the U.S. Food and Drug Administration, according to a Wednesday disclosure on the Shenzhen bourse.
The Chinese pharmaceutical company's shares rose 4% during Thursday's afternoon trade.
The drug is developed by the company's subsidiary, CSPC Giant Biopharmaceutical, as a treatment for patients with microsatellite-stable or mismatch repair-proficient metastatic colorectal cancer.